Literature DB >> 17339454

Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.

Dianne Khurana1, Laura N Arneson, Renee A Schoon, Christopher J Dick, Paul J Leibson.   

Abstract

NK cells are effector lymphocytes that can recognize and eliminate virally infected and transformed cells. NK cells express distinct activating receptors, including an ITAM-containing FcR complex that recognizes Ab-coated targets, and the DNAX-activating protein of 10 kDa-containing NKG2D receptor complex that recognizes stress-induced ligands. The regulatory role of specific tyrosine kinases in these pathways is incompletely understood. In this study, we show that, in activated human NK cells, the tyrosine kinase IL-2-inducible T cell kinase (Itk), differentially regulates distinct NK-activating receptors. Enhanced expression of Itk leads to increases in calcium mobilization, granule release, and cytotoxicity upon stimulation of the ITAM-containing FcR, suggesting that Itk positively regulates FcR-initiated cytotoxicity. In contrast, enhanced Itk expression decreases cytotoxicity and granule release downstream of the DNAX-activating protein of 10 kDa-containing NKG2D receptor, suggesting that Itk is involved in a pathway of negative regulation of NKG2D-initiated granule-mediated killing. Using a kinase mutant, we show that the catalytic activity of Itk is required for both the positive and negative regulation of these pathways. Complementary experiments where Itk expression was suppressed also showed differential regulation of the two pathways. These findings suggest that Itk plays a complex role in regulating the functions initiated by distinct NK cell-activating receptors. Moreover, understanding how these pathways may be differentially regulated has relevance in the setting of autoimmune diseases and antitumor immune responses where NK cells play key regulatory roles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339454     DOI: 10.4049/jimmunol.178.6.3575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

2.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 3.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

4.  Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse.

Authors:  Emanuele Giurisato; Marina Cella; Toshiyuki Takai; Tomohiro Kurosaki; Yungfeng Feng; Gregory D Longmore; Marco Colonna; Andrey S Shaw
Journal:  Mol Cell Biol       Date:  2007-10-08       Impact factor: 4.272

5.  ITK Gene Mutation: Effect on Survival of Children with Severe Hemophagocytic Lymphohistiocytosis.

Authors:  Fang Zheng; Juan Li; Hui Zha; Jue Zhang; Zhiquan Zhang; Fangjun Cheng
Journal:  Indian J Pediatr       Date:  2016-04-08       Impact factor: 1.967

6.  Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Authors:  Thijs W H Flinsenberg; Charnelle C Tromedjo; Nan Hu; Ye Liu; Yin Guo; Kevin Y T Thia; Tahereh Noori; Xiaomin Song; Han X Aw Yeang; Daniela G Tantalo; Sasanka Handunnetti; John F Seymour; Andrew W Roberts; David Ritchie; Rachel Koldej; Paul J Neeson; Lai Wang; Joseph A Trapani; Constantine S Tam; Ilia Voskoboinik
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

7.  The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Authors:  Josée Golay; Greta Ubiali; Martino Introna
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

8.  Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Authors:  Holbrook E Kohrt; Idit Sagiv-Barfi; Sarwish Rafiq; Sarah E M Herman; Jonathon P Butchar; Carolyn Cheney; Xiaoli Zhang; Joseph J Buggy; Natarajan Muthusamy; Ronald Levy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

9.  Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis.

Authors:  Guang Zheng; He Zhang; Yun Yang; Ying-Li Sun; Yan-Jing Zhang; Ju-Ping Chen; Ting Hao; Cheng Lu; Hong-Tao Guo; Ge Zhang; Dan-Ping Fan; Xiao-Juan He; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

Review 10.  Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Authors:  Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.